MIST Milestone Pharmaceuticals Inc.

2.11
+0.34  (+19%)
Previous Close 1.77
Open 1.8
Price To Book 0.45
Market Cap 51,820,482
Shares 24,559,470
Volume 2,922,326
Short Ratio
Av. Daily Volume 660,065
Stock charts supplied by TradingView

NewsSee all news

  1. Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment

    – Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12) – – Etripamil showed rapid conversion of SVT to SR during the first 45 minutes (p=0.02),

  2. Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update

    – Topline data from Phase 3 NODE-301 trial of etripamil in patients with PSVT expected this month –  MONTREAL and CHARLOTTE, N.C., March 6, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a

  3. Canadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach

    TORONTO, Nov. 27, 2019 /CNW/ - Canadian venture capital (VC) disbursements are continuing red-hot record-setting pace, completing 452 financings totalled $5.1billion (excluding Verafin deal1) in the first three quarters

  4. Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

    MONTREAL and CHARLOTTE, N.C., Nov. 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the following

  5. Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update

    – NODE-301 topline data readout expected in mid-1H20 – – Richard Pasternak, M.D. appointed to the Company's Board of Directors – MONTREAL and CHARLOTTE, N.C., Nov. 13, 2019 /PRNewswire/ -- Milestone Pharmaceuticals

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial planned.
Etripamil
Angina
Phase 2 trial to be initiated in 2020.
Etripamil
Atrial fibrillation
Phase 3 open label data due 1H 2021.
Etripamil - NODE-302
Paroxysmal supraventricular tachycardia (PSVT)
Phase 3 top-line data released March 23, 2020 did not meet primary endpoint.
Etripamil - NODE-301
Paroxysmal supraventricular tachycardia (PSVT)
Phase 3 open label commencement of dosing announced October 3, 2019.
Etripamil - NODE-303
Paroxysmal supraventricular tachycardia (PSVT)

Latest News

  1. Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment

    – Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12) – – Etripamil showed rapid conversion of SVT to SR during the first 45 minutes (p=0.02),

  2. Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update

    – Topline data from Phase 3 NODE-301 trial of etripamil in patients with PSVT expected this month –  MONTREAL and CHARLOTTE, N.C., March 6, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a

  3. Canadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach

    TORONTO, Nov. 27, 2019 /CNW/ - Canadian venture capital (VC) disbursements are continuing red-hot record-setting pace, completing 452 financings totalled $5.1billion (excluding Verafin deal1) in the first three quarters

  4. Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

    MONTREAL and CHARLOTTE, N.C., Nov. 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the following

  5. Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update

    – NODE-301 topline data readout expected in mid-1H20 – – Richard Pasternak, M.D. appointed to the Company's Board of Directors – MONTREAL and CHARLOTTE, N.C., Nov. 13, 2019 /PRNewswire/ -- Milestone Pharmaceuticals

  6. Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT

    MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment

  7. Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT

    MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the

  8. Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development

    MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the

  9. Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development

    MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the